| Popis: |
Content 1. Chapter 1: Introduction to Therapeutic Drug Monitoring. Amitava Dasgupta, Ph.D. Department of Pathology and Laboratory Medicine, University of Texas-Houston, Medical School, Houston, TX 2. Chapter 2. Monitoring Free Drug Concentration. Amitava Dasgupta, Ph.D. Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, Houston, TX. 3. Chapter 3. Analytical Techniques for Measuring Concentrations of Therapeutic Drugs in Biological Fluids. Amitava Dasgupta and Pradip Datta. Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, Houston, Texas and Bayer HealthCare, Diagnostics Division, Tarrytown, NY 4. Chapter 4. The Pre-Analytical Phase of Drug Testing: From Specimen Collection to Analysis. Catherine A. Hammett-Stabler, Ph.D. Department of Pathology and Laboratory Medicine University of North Carolina at Chapel Hill 5. Chapter 5. Effect of Hemolysis, High Bilirubin, Lipemia, Paraproteins and System Factors on Therapeutic Drug Monitoring. Pradip Datta, PhD. Bayer HealthCare, Diagnostics Division, Tarrytown, NY 6. Chapter 6: Digoxin: So Many Interferences and How to Eliminate Them. Amitava Dasgupta, Ph.D. Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, Houston, TX 7. Chapter 7. Interferences with Measurement of Anticonvulsants. William Clarke, Ph.D. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 8. Chapter 8. Pitfalls in Measuring Antidepressant Drugs. Uttam Garg, Ph.D. Department of Pathology and Laboratory Medicine University of Missouri, Kansas City and Children's Mercy Hospitals and Clinics, Kansas City, MO. 9. Chapter 9. Immunosuppressive Drugs: Pharmacokinetics, Preanalytic Variables, and Analytical Considerations. Anthony W. Butch, Ph.D. Department of Pathology and Laboratory Medicine, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095-1732 10. Chapter 10. Therapeutic Drug Monitoring in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. Steven J Soldin PhD. Department of Pharmacology, Georgetown University and Department of Laboratory Medicine, Children's National Medical Center 11. Chapter 11. Pharmacogenomics and Personalized Medicine: Issues and Methodology. Steven H. Y. Wong. Department of Pathology, Medical College of Wisconsin And Toxicology Department, Milwaukee County Medical Examiner's Office, Milwaukee, WI, 12. Chapter 12. Interference of Heterophilic and Other Antibodies in Measurement of Therapeutic Drugs by Immunoassays. Pradip Datta, PhD. Bayer HealthCare, Diagnostics Division, Tarrytown, NY 13. Chapter 13. Drug-Herb and Drug-Food Interactions: Impact on Therapeutic Drug Monitoring. Amitava Dasgupta, Ph.D Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, Houston, TX 14. Chapter 14. Toxic Element Testing with Clinical Specimens. Gwendolyn A. McMillin, Ph.D.1,2 and Joshua A. Bornhorst, Ph.D. 3 1 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, 2 Department of Pathology, University of Utah, Salt Lake City, Utah 84132, 3 Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 15. Chapter 15. Alcohol Testing. Steve C. Kazmierczak, Ph.D and Hassan ME Azzazy, Ph.D. Department of Pathology, Oregon Health & Science University, Portland, Oregon and Department of Chemistry, The American University of Cairo, Egypt 16. Chapter 16. Introduction to Drugs of Abuse Testing. Tai C. Kwong, Ph.D. Department of Pathology, University of Rochester Medical Center, Rochester, NY 17. Chapter 17. Urinary |
